Document Detail


Angiotensin II activates NADPH oxidase in isolated rat hearts subjected to ischaemia-reperfusion.
MedLine Citation:
PMID:  12591107     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The role of angiotensin II in myocardial ischaemia-reperfusion is not clearly defined. In this respect, the involvement of NADPH oxidase remains to be determined. The aim of this study was 1) to evaluate the cardiac effects of angiotensin AT(1) receptor stimulation in non-ischaemic conditions of perfusion or during ischaemia-reperfusion, and 2) to measure the concomitant activation of NADPH oxidase in isolated rat hearts perfused with angiotensin II and/or Losartan. In non-ischaemic hearts, angiotensin II induced rapid and prolonged vasoconstrictive and negative inotropic effects. Ischaemia-reperfusion increased the mRNA expression of AT(1) and AT(2) receptors. During reperfusion, angiotensin II reduced the incidence of arrhythmias and the lactate dehydrogenase released, and increased NADPH oxidase mRNA expression and enzyme activity. Losartan co-administration totally antagonised the effects of angiotensin II. Our study demonstrates that ischaemia-reperfusion induces adaptative cardiac modifications, which allow exogenously added angiotensin II to stimulate myocardial NADPH oxidase through angiotensin AT(1) receptor activation.
Authors:
Alexandra Oudot; Catherine Vergely; Aline Ecarnot-Laubriet; Luc Rochette
Related Documents :
3180357 - Superoxide dismutase conjugated to polyethylene glycol provides sustained protection ag...
25446877 - Galectin-3 and heart failure: prognosis, prediction & clinical utility.
11605997 - Nifedipine limits infarct size via no-dependent mechanisms in dogs.
2297827 - Occurrence of oxidative stress during reperfusion of the human heart.
23367457 - Assessment of hemodynamic load components affecting optimization of cardiac resynchroni...
1244257 - Echocardiographic spectrum of ebstein's anomaly of the tricuspid valve.
Publication Detail:
Type:  In Vitro; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  European journal of pharmacology     Volume:  462     ISSN:  0014-2999     ISO Abbreviation:  Eur. J. Pharmacol.     Publication Date:  2003 Feb 
Date Detail:
Created Date:  2003-02-19     Completed Date:  2003-07-02     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  1254354     Medline TA:  Eur J Pharmacol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  145-54     Citation Subset:  IM    
Affiliation:
Laboratoire de Physiopathologie et Pharmacologie Cardio-vasculaires Expérimentales, Faculties of Medicine and Pharmacy, 7, Boulevard Jeanne d'Arc, BP 87900, 21079 Dijon, France. aoudot@hotmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin II / pharmacology*
Animals
Arrhythmias, Cardiac / physiopathology,  prevention & control
Coronary Circulation / drug effects
Enzyme Activation / drug effects
Heart / drug effects*,  physiology,  physiopathology
L-Lactate Dehydrogenase / drug effects,  metabolism
Losartan / pharmacology
Male
Membrane Glycoproteins / genetics
Membrane Transport Proteins*
Myocardial Ischemia / complications*
Myocardial Reperfusion Injury / etiology,  physiopathology*,  prevention & control
Myocardium / enzymology*,  metabolism
NADPH Dehydrogenase / genetics
NADPH Oxidase / genetics,  metabolism*
Perfusion
Phosphoproteins / genetics
RNA, Messenger / drug effects,  genetics,  metabolism
Rats
Rats, Wistar
Vasoconstrictor Agents / pharmacology
Ventricular Function, Left / drug effects,  physiology
Chemical
Reg. No./Substance:
0/CYBB protein, human; 0/Membrane Glycoproteins; 0/Membrane Transport Proteins; 0/Phosphoproteins; 0/RNA, Messenger; 0/Vasoconstrictor Agents; 11128-99-7/Angiotensin II; 114798-26-4/Losartan; EC 1.1.1.27/L-Lactate Dehydrogenase; EC 1.6.3.1/CYBA protein, human; EC 1.6.3.1/NADPH Oxidase; EC 1.6.99.1/NADPH Dehydrogenase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effect of a single dose aspirin on platelets in humans with multiple risk factors for coronary arter...
Next Document:  The effect of chronic renal failure on phosphodiesterase inhibitor-induced relaxation responses in r...